Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs

被引：0
|
作者：
Lee, S. H. [1 ]
Park, M. J. [1 ]
Chang, B. [1 ]
机构：
[1] Kyung Hee Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-TKIs; programmed death ligand; Clinical outcome;
D O I：
10.1016/j.jtho.2019.08.1195
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-44
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [21] Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [22] Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer
    Lei, Si-Yu
    Xu, Hai-Yan
    Li, Hong-Shuai
    Yang, Ya-Ning
    Xu, Fei
    Li, Jun-Ling
    Wang, Zhi-Jie
    Xing, Pu-Yuan
    Hao, Xue-Zhi
    Wang, Yan
    THORACIC CANCER, 2023, 14 (24) : 2327 - 2337
  • [23] EGFR-TKIs resistance promotes immune escape of lung cancer through increasing PD-L1 expression
    Wang, Wei
    Peng, Shunli
    Li, Qi
    Wang, Rong
    Zhang, Xiaojuan
    CANCER SCIENCE, 2018, 109 : 284 - 284
  • [24] The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
    Tang, Yanna
    Fang, Wenfeng
    Zhang, Yaxiong
    Hong, Shaodong
    Kang, Shiyang
    Yan, Yue
    Chen, Nan
    Zhan, Jianhua
    He, Xiaobo
    Qin, Tao
    Li, Ge
    Tang, Wenyi
    Peng, Peijian
    Zhang, Li
    ONCOTARGET, 2015, 6 (16) : 14209 - 14219
  • [25] Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma.
    Jiang, Kan
    Lin, Gen
    Zheng, Xinlong
    Long, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Sung, Ji-Youn
    Park, Dong-Won
    Lee, Seung-Hyeun
    BIOMEDICINES, 2022, 10 (09)
  • [27] Clinical Benefit of EGFR-TKIs Plus Radiotherapy for Treating EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer
    Li, T.
    Wang, R.
    Lv, J.
    Sun, C.
    Shi, Q.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E516 - E517
  • [28] Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs
    Niu, Jiling
    Jing, Xuquan
    Xu, Qinhao
    Liu, Haoyu
    Tian, Yaru
    Yang, Zhengqiang
    Zhu, Hui
    Sun, Yulan
    FUTURE ONCOLOGY, 2024, 20 (32) : 2481 - 2490
  • [29] High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Chen, Kun-Chieh
    Ku, Wen-Hui
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chen, Huei-Wen
    Yu, Sung-Liang
    Yang, Tsung-Ying
    Chang, Gee-Chen
    LUNG CANCER, 2019, 127 : 37 - 43
  • [30] Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.
    Wang, Ran Lin
    Li, Tao
    Lv, Jiahua
    Sun, Chang
    Shi, Qiuling
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345